RNS Number: 3053 V Indivior PLC 02 December 2019 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at December 1, 2019 the Company's issued share capital consisted of 730,765,489 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 2352 V Indivior PLC 02 December 2019 New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes. -Sustained improvements in multiple health outcomes following twelve monthly buprenorphine extended-release injections in patients with opioid use disorder-.
RNS Number: 0410 T Indivior PLC 12 November 2019 Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder and to Let People with OUD Know That They Can "Keep Moving Towards Recovery". -Only 20% of people suffering from the disease receive any kind of treatment-. Richmond, VA, November 12, 2019- Indivior PLC announces...
RNS Number: 9465 S Indivior PLC 11 November 2019 BLOCK LISTING SIX MONTHLY RETURN. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5382 S Indivior PLC 06 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2085 S Indivior PLC 04 November 2019. Indivior to Participate in Upcoming Investor Conferences. Slough, UK, and Richmond, VA- 4 November 2019- Indivior PLC today announced that it will participate in the following Investor Conferences the week of November 18th.
RNS Number: 8506 R Indivior PLC 31 October 2019 Indivior PLC- Board Committee Changes. Slough, UK and Richmond, VA, October 31, 2019- Indivior PLC announces that Graham Hetherington will be appointed a member of the Remuneration Committee with effect from November 1, 2019.. RNS is approved by the Financial Conduct Authority to act as a Primary Information...
·Total net revenue of $652 m declined 15% versus YTD 2018. U.S. net revenue declined 16% primarily due to SUBOXONE ® Film share loss to generic competitors, albeit at a lower rate than suggested by historical industry analogues 1. The impact of share loss was partially offset by good underlying market growth for buprenorphine medication-assisted treatment,...
RNS Number: 0498 Q Indivior PLC 16 October 2019 Indivior PLC- Directorate Change. Slough UK and Richmond VA October 16, 2019- The Board of Indivior PLC is pleased to announce the appointment of Graham Hetherington as an independent Non-Executive Director of the Company with effect from November 1, 2019. He was previously Chief Financial Officer of Shire PLC, a...
Slough, UK, and Richmond, VA, 15 October 2019- Indivior PLC today announced revised expectations for FY 2019 net revenue and net income following stronger-than-expected net revenue performance. FY 2019 Group net revenue is now expected to be in the range of $750 m to $790 m and net income in the range of $160 m to $190 m, excluding exceptional items and F/X.
RNS Number: 5644 O Indivior PLC 03 October 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0382 O Indivior PLC 01 October 2019 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at October 1, 2019 the Company's issued share capital consisted of 730,737,398 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 0385 O Indivior PLC 01 October 2019. Slough, UK, and Richmond, VA- 1 October 2019- Indivior PLC today announced that it will release its 2019 year-to-date and third quarter results on Thursday, October 31st at 11:00 London time. Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss...
RNS Number: 9252 N Indivior PLC 27 September 2019. Announcement of National Institutes of Health Grant Award through the NIH Helping to End Addiction Long-term Initiative. Slough, U.K. and Richmond, VA, 27 September, 2019- Indivior PLC announces that the National Institutes of Health has granted Indivior's application entitled " Clinical Evaluation of C4X3256, a...
RNS Number: 8617 N Indivior PLC 27 September 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8989 K Indivior PLC 02 September 2019 INDIVIOR PLC- TOTAL VOTING RIGHTS AND CAPITAL. In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6. 1, the Company hereby notifies the market that as at September 1, 2019 the Company's issued share capital consisted of 730,732,543 O rdinary Shares of US $0.10 each. RNS is approved by the...
RNS Number: 9016 I Indivior PLC 13 August 2019 INDIVIOR PLC. The Company announces that it received notification on August 13, 2019 that Lorna Parker, a Non-Executive Director of the Company, acquired 8,282 shares at a price of £0.603707 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
The Company announces that it received notification on August 8, 2019 that Howard Pien, Chair, acquired 50,000 shares at a price of $0.746725 per share on August 7, 2019 and acquired a further 50,000 shares at the price of $0.7359 per share on August 8, 2019. The Company also announces that it received notification on August 8, 2019 that Peter Bains, a...
RNS Number: 4167 I Indivior PLC 08 August 2019 INDIVIOR PLC. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM. The Company announces that on August 8, 2019 it granted a Conditional Award over Ordinary Shares of US $0.10 each in the Company under the Indivior...
RNS Number: 1156 I Indivior PLC 06 August 2019 INDIVIOR PLC. The Company announces that it received notification on August 6, 2019 that Mark Crossley, Chief Financial and Operations Officer, acquired 63,291 shares at a price of $0.7314 per share. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
--
-
Ask
- High-
- OPEN-
- VOL-
- MKT CAP-m
- LOW-
- CLOSE-
- AVG VOL-
- SHARES IN ISSUE730.03M
Company Profile
Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.
Classification
| Market Indices | - |
Locations
| HQ | 103-105 Bath Road Slough SL1 3UH |